Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)
Authors:
- Kara NunleyKNKara Nunley
- Michael P. HeffernanMHMichael P. Heffernan
- 1 January 2007
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 56 (1) , e55-e79
Abstract
No abstract availableKeywords
This publication has 265 references indexed in Scilit:
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Treatment of recalcitrant atopic dermatitis with omalizumabJournal of the American Academy of Dermatology, 2006
- Ulcerative cutaneous sarcoidosis responding to adalimumabJournal of the American Academy of Dermatology, 2005
- Failure of omalizumab for treatment of severe adult atopic dermatitisJournal of the American Academy of Dermatology, 2005
- A case of mucocutaneous Behçet's disease responding to etanerceptJournal of the American Academy of Dermatology, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Role of tumor necrosis factor-α in Sneddon-Wilkinson subcorneal pustular dermatosisJournal of the American Academy of Dermatology, 1991